Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, CanadaDr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
Disclosures
Dr. Lin has consulted with the following companies on Continuing Medical Education programs:Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Very High Coronary Artery Calcium and Association With CVD Events, Non-CVD Outcomes, and Mortality
- Tocilizumab in Hospitalized Patients With Severe COVID-19 Pneumonia
- IL-6 Receptor Antagonists in Severe COVID-19
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- Early Initiation of Prophylactic Anticoagulation Reduces COVID-19 Mortality in Patients Admitted to the Hospital
- Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine
- J&J COVID-19 Vaccine 66 Percent Effective in Interim Analysis
- New COVID-19 Variants May Weaken Efficacy of Vaccines
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer–BioNTech COVID-19 Vaccine
- 2.5 Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots